Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 |
| clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06456892 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | recruiting | Phase 1 / Phase 2 | 82 | Sun Yat-sen UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | recruiting | Phase 1 | 48 | Rong TaoOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06109558 | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC(PROFILE) | recruiting | Phase 1 / Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05911217 | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer | recruiting | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT06204835 | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery | recruiting | Phase 1 | 90 | Institute of Automation, Chinese Academy of SciencesOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06403735 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 250 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03685890 | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion(NivoILP) | recruiting | Phase 1 / Phase 2 | 74 | Vastra Gotaland RegionOTHER_GOV | 2 | Apr 25, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02889666 | A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC) | recruiting | Phase 1 | 500 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast(COC-IDCB) | recruiting | Phase 1 | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL(AETHER) | recruiting | Phase 1 / Phase 2 | 112 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Apr 12, 2024 | clinicaltrials |
| NCT06087341 | A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma(CAR4SAR) | recruiting | Phase 1 | 18 | Antonio Pérez MartínezOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363006 | Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer | recruiting | Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06340204 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | recruiting | Phase 1 | 44 | Peking University People's HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Etnova Therapeutics Corp.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05877924 | A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 200 | NovaRock Biotherapeutics, LtdINDUSTRY | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT04243785 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 80 | Edgewood Oncology Inc.INDUSTRY | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 164 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | recruiting | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06270017 | Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars(ZEBRA-COLON) | recruiting | Phase 1 / Phase 2 | 300 | University Hospital, LinkoepingOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04165590 | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06223841 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 50 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2024source: clinicaltrials